Staurosporine

製品コードS1421 別名:CGP 41251

Staurosporine化学構造

分子量(MW):466.53

Staurosporineは1種の有効なPKC阻害剤で、無細胞試験でPKCα、PKCγ とPKCηに作用します。そして、これらのIC50値は2 nM、5 nM と 4 nMそれぞれに分かれます。StaurosporineはPKCδ(20 nM)とPKCε(73 nM)に作用することが弱くて、PKCζ (1086 nM)に対する活性も低いですが、他のキナーゼ(例えば、PKA、PKG、S6K、CaMKII等)に抑制活性を現れます。臨床3期。

サイズ 価格 在庫  
JPY 38876.76 あり

カスタマーフィードバック(3)

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

製品安全説明書

PKC阻害剤の選択性比較

生物活性

製品説明 Staurosporineは1種の有効なPKC阻害剤で、無細胞試験でPKCα、PKCγ とPKCηに作用します。そして、これらのIC50値は2 nM、5 nM と 4 nMそれぞれに分かれます。StaurosporineはPKCδ(20 nM)とPKCε(73 nM)に作用することが弱くて、PKCζ (1086 nM)に対する活性も低いですが、他のキナーゼ(例えば、PKA、PKG、S6K、CaMKII等)に抑制活性を現れます。臨床3期。
ターゲット
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外試験

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells M3rIc2N6fG:2b4jpZ:Kh[XO|YYm= MkW2OFghcA>? M{C0dGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20[U0xPiEQvF2u NYLjN4pjOjF|OEixPVE>
human colon cancer cell line (LoVo cells) M{HufXBzd2yrZnXyZZRqd25iYYPzZZk> MmrlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiClb3zvckBk[W6lZYKgZ4VtdCCuaX7lJEhNd1[xIHPlcIx{MSC3c3nu[{BOXFRiYYPzZZktKEmFNUC9NE4xODFizszNMi=> MlXlNVE2QTF3MEW=
human LoVo cells Mkf3VJJwdGmoZYLheIlwdiCjc4PhfS=> MX:0PEB1dyB5MjDo M{HsTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6 NVPlbHduOjJzOEK5Nlk>
P19 cells M17WSmZ2dmO2aX;uJIF{e2G7 M{nyVmlvcGmkaYTpc44hd2ZiUHzheIVt\XRvZHXybZZm\CCpcn;3eIgh\mGldH;yJJJm[2WydH;yJIlvKFBzOTDj[YxteyxiSVO1NF0xNjByMjFOwG0v MnjBNVU4PzF2MUm=
human BJ cells NULFcFYxS3m2b4TvfIlkyqCjc4PhfS=> NX;lTI14PzJiaB?= M1X0UWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJLKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTBwMECyJO69VS5? M4jUPVIzQTJzMEix
human HT-29 cells NICyfY5HfW6ldHnvckBie3OjeR?= NUD2cGNqOiCq MkeySYZn\WO2IH;uJI1qfG:laH;u[JJq[WxibXXtZpJidmVicH;0[Y51cWGuIHnuJIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEKgbJJ{KHW|aX7nJGpENTFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGG|c3H5 MXmyNVQzQDN5NR?=
human A549 cells MlzpR5l1d3SxeHnjxsBie3OjeR?= MlPRO|IhcA>? NUXQ[2gzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3S= M3ft[lE5PDh2N{e1
human HT-29 cells NH7peFdHfW6ldHnvckBie3OjeR?= NEHZT2FKdmirYnn0bY9vKG:oIH3peI9kcG:wZILpZYwhdWWvYoLhcoUheG:2ZX70bYFtKGmwIHj1cYFvKEiWLUK5JINmdGy|IIXzbY5oKEqFMTDkfYUhe3SjaX7pcoch[nliZnz1c5Jme2OnbnPlJJBt[XSnIILlZYRmeiCjc4PhfUwhUUN3ME2yMlUhdk1? MnvHNlE2OTN{OUO=
human HT-29 cells M2CzZ2Z2dmO2aX;uJIF{e2G7 MlHINkBp MkHlTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDy[YR2[3Srb36gc4YhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDwc5RmdnSrYXygZYZ1\XJiMjDodpMh[nlidYPpcochUkNzIIP0ZYlvcW6pIHL5JIZtfW:{ZYPj[Y5k\SClZXzsMYJie2WmIHHzd4F6NCCHQ{WwQVIvPiCwTT6= M2DSW|IyQTd|MUCx
Sf9 cells MnfMSpVv[3Srb36gZZN{[Xl? M{\Xc2lvcGmkaYTpc44hd2ZiaIXtZY4hW3mtIHX4dJJme3OnZDDpckBU\jliY3XscJMtKEmFNUC9N{BvVS5? M1\wfVE5QDJ|N{i0
human HUVEC MWnQdo9tcW[ncnH0bY9vKGG|c3H5 NV2zWHJ5PDhidH:gO|IhcA>? Ml[5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVW\FR{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7 MXSyNlE5Ojl{OR?=
P19 cells NGHKN3BHfW6ldHnvckBie3OjeR?= NG[1T5VKdmirYnn0bY9vKG:oIGDyc5RmcW5iS3nuZZNmKEFiaX6gVFE6KGOnbHzzMEBKSzVyPUSgcm0v Mn;ZNVU4PzF2MUm=
Sf9 cells NFzBXVlHfW6ldHnvckBie3OjeR?= M1;PbGlvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBucW5iYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSS Mn3jNVc{OTV6NUO=
Sf21 cells M{T2VmZ2dmO2aX;uJIF{e2G7 Mlq5TY5pcWKrdHnvckBw\iCMQVuzJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy|LDDJR|UxRTZibl2u MVWxO|A5QDB3OR?=
human colon carcinoma cell line HCT116 NGS5ZVZHfW6ldHnvckBie3OjeR?= NX3oenNDS2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> MYSxOVU{PzN2NR?=
human ST486 cells NH62fJBRem:uaX\ldoF1cW:wIHHzd4F6 NH3VRVY1QCC2bzC3NkBp MojrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVVES4OkBk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVchdk1w NUfaV49vOjJzOEK5Nlk>
human MDA-MB-231 cells NYSzVI93S3m2b4TvfIlkyqCjc4PhfS=> NX[4N5ZPPzJiaB?= NGHBbmxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIH3leIhw\CxiR1m1NF04NjFibl2u NEPufZMyQDR6NEe3OS=>
P19 cells M{Kxc2Z2dmO2aX;uJIF{e2G7 NH7jVoFKdmirYnn0bY9vKG:oIFP5Z4xqdi2mZYDlcoRmdnRia3nuZZNmKDFiaX6gVFE6KGOnbHzzMEBKSzVyPUigcm0v MXSxOVc4OTRzOR?=
human DLD1 cells NV7HfGlDWHKxbHnm[ZJifGmxbjDhd5NigQ>? NYTsNIgzPDhvN{KgbC=> Mo\KRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? Mof3NlIyQDJ7Mkm=
insect cells MYPGeY5kfGmxbjDhd5NigQ>? MkPGTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSaX2xJIV5eHKnc4Pl[EBqdiCrboPlZ5Qh[2WubIOgZpkhUFSURjygTWM2OD1zMDDuUU4> NH7zV2oyQTF5OUC3Oi=>
V79 MZ cells MWXGeY5kfGmxbjDhd5NigQ>? M{DySWlvcGmkaYTpc44hd2ZiaIXtZY4h[Wymb4P0[ZJwdmVic4nueIhie2ViZYjwdoV{e2WmIHnuJHY4QSCPWjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGuZH;zeIVzd26nIIP5cpRp\XOrczygTWM2OD1zMTDuUU4> MkPjNlQ1OjJ3MUm=
P19 cells NIfafFFHfW6ldHnvckBie3OjeR?= MmW0TY5pcWKrdHnvckBw\iCYYYPjeYxieiCnbnTveIhmdGmjbDDndo94fGhiZnHjeI9zKHKnY3XweI9zKGmwIGCxPUBk\WyuczygTWM2OD1zNDDuUU4> NYfkVoxEOTV5N{G0NVk>
Sf9 cells MV\GeY5kfGmxbjDhd5NigQ>? MnXiNlAhdWmwcx?= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEKwJI1qdnNiYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSSLDDJR|UxRTF3IH7NMi=> MkLpNVc{OTV6NUO=
human PBMC NXfNTIt{TnWwY4Tpc44h[XO|YYm= MWSyOEBp MXXTeZBxemW|c3nvckBw\iCLTEKgdJJw\HWldHnvckBqdiCqdX3hckBRSk2FIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRUwhUUN3ME2xOkBvVS5? M{S1fFE5PTh3MES2
human A549 cells NEfYd4REgXSxdH;4bYPDqGG|c3H5 NFPu[oo1QCCq M2nnfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9NlAhdk1w NFW2[IIzPTh{NUmzOC=>
human CEM cells MWnDfZRwfG:6aXRCpIF{e2G7 NYXIfXd1PzJiaB?= NHL3cXdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v M1\aWlIzQTJzMEix
human HeLa cells MYHDfZRwfG:6aXRCpIF{e2G7 NVLnbIZmPDhiaB?= M2LkN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yOUBvVS5? MY[yOVgzPTl|NB?=
human PC3 cells NUL6UpE4S3m2b4TvfIlkyqCjc4PhfS=> NYXtUXluPDhiaB?= MmjjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgMEBKSzVyPUOxJI5ONg>? MVyyOVgzPTl|NB?=
human SF268 cells Mm\XR5l1d3SxeHnjxsBie3OjeR?= Mn;4OFghcA>? NX75fZJuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= MmPONlE2OTN{OUS=
human MCF7 cells M1XtfWN6fG:2b4jpZ:Kh[XO|YYm= M2j1RVQ5KGh? NEn0T|dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OVAhdk1w MUSyNVM5QDF7MR?=
HEK293 cells NV:5PIJLS3m2b4TvfIlkyqCjc4PhfS=> NUi1[IM6PzJiaB?= NXz3PJE4S3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYLHcI8h[XO|YYmsJGlEPTB;NU[gcm0v NVTMTodlOjR5NkOyOlI>
HUE cells M3vqOmZ2dmO2aX;uJIF{e2G7 NXHnb3BRQTBibXnudy=> MULJcohq[mm2aX;uJI9nKF[HR1\SNkBqdiCKVVWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB1emWjdHXkJIZweiB7MDDtbY5{KGKnZn;y[UBXTUeIIHPoZYxt\W6pZTDifUBGVEmVQTygTWM2OD15MDDuUU4> M2n5VFIxOTdyMU[z
human A431 cells NIL4T49EgXSxdH;4bYPDqGG|c3H5 MWWyOEAhcA>? M4L0OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgNlQhcHK|IIXzbY5oKEGwbnX4bY4hXmWISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZpkhVVSWIHHzd4F6NCCLQ{WwQVcxKG6PLh?= NVfCfYtQOjJ3NEGwOVE>
human Jurkat cells M3\rRXBzd2yrZnXyZZRqd25iYYPzZZk> MnLhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDKRWs{KGW6cILld5NqdmdiSVyyMZN1cW23bHH0[YQhcHWvYX6gTpVzc2G2IHPlcIx{NCCLQ{WwQVcyKG6PLh?= NVHYTWNSOTl2MkeyNFM>
HEK293 cells MYfGeY5kfGmxbjDhd5NigQ>? M3vRUmlvcGmkaYTpc44hd2ZiSVytPEBz\WynYYPlJIJ6KEiHS{K5N{Bk\WyuczDlfJBz\XO|aX7nJHBMSy2kZYThNkwhUUN3ME23O{BvVS5? M{f5c|E2PzdzNEG5
human KE-97 cells MlPuR5l1d3SxeHnjxsBie3OjeR?= M1fiU|czKGh? NFW5[mhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMTS17NzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|IN88UU4> MoK2NlQ{Ojh{OEO=
human CHOK1 cells Mn\4R5l1d3SxeHnjxsBie3OjeR?= MlrVOFghcA>? MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDTG9MOSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H589yNKEmFNUC9NE4yOyEQvF2u NHf5fYkzOTVzM{K5OC=>
mouse NIH/3T3 cells NG\WfphEgXSxdH;4bYPDqGG|c3H5 NU\YbG1jQTZiaB?= Mn\oR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUmlJNzOWMzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u M2W4dFI1OzZzNUKx
human A2780 cells M3;rOWN6fG:2b4jpZ:Kh[XO|YYm= NEjONZA6PiCq MlvVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= NWH5UIRWOjR|NkG1NlE>
human 8505C cells M4ftVmN6fG:2b4jpZ:Kh[XO|YYm= MUS5OkBp NI\NfpdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA5PTB3QzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u NGnmeXUzPDN4MUWyNS=>
human 518A2 cells MmfiR5l1d3SxeHnjxsBie3OjeR?= MWO5OkBp M4\GUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFUyQEF{IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjJizszNMi=> MUmyOFM3OTV{MR?=
human HuH7 cells MXvDfZRwfG:6aXRCpIF{e2G7 NIXvVGQ4OiCq MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlMh|ryPLh?= NIe4UYQzPDN{OEK4Ny=>
FL5.12-Akt1 cells MX;Qdo9tcW[ncnH0bY9vKGG|c3H5 NV3lUFY5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBHVDVwMUKtRYt1OSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5{OTFOwG0v MXyxOlQxOzZ{Nh?=
human MiaPaCa-2 cells NYHJUlh1WHKxbHnm[ZJifGmxbjDhd5NigQ>? NH3ZRYpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3pZXBiS2FvMjDj[YxteyxiSVO1NF0xNjN5IN88UU4> MUSxOlQyOzd6MB?=
human BGC823 cells NH;Ue3NEgXSxdH;4bYPDqGG|c3H5 MmX3O|IhcA>? MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QCEQvF2u NHjXb3ozPDN{OEK4Ny=>
human MCF7 cells MnuzR5l1d3SxeHnjxsBie3OjeR?= NYnm[Y12QTZiaB?= Mn;UR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOEDPxE1w MnXxNlQ{PjF3MkG=
human A549 cells M3m3TWN6fG:2b4jpZ:Kh[XO|YYm= M3G5dVk3KGh? MnSxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOkDPxE1w MmX0NlQ{PjF3MkG=
HEK293 cells MoDqR5l1d3SxeHnjxsBie3OjeR?= NF3vRoFEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOsJGVEPTB;MjFOwG0v MVeyOVMyPjNzNx?=
human Raji cells  M2nSUGN6fG:2b4jpZ:Kh[XO|YYm= NILyOpREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[WqrIHPlcIx{NCCHQ{WwQVIh|ryPLh?= NWPmbWtrOjV|MU[zNVc>
human HepG2 cells MojuR5l1d3SxeHnjxsBie3OjeR?= M4HBbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{NCCHQ{WwQVIh|ryPLh?= MoLHNlU{OTZ|MUe=
human BJ cells M4fKZWN6fG:2b4jpZ:Kh[XO|YYm= NVnqUm1tS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMtKEWFNUC9NkDPxE1w NFXjUIUzPTNzNkOxOy=>
human U937 cells MX7DfZRwfG:6aXRCpIF{e2G7 M3nTdmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NkDPxE1w MUGxO|A5QDB4Nx?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
細胞試験:

[3]

+ 展開
  • 細胞株: PC12
  • 濃度: Dissolved in DMSO, final concentration 1 μM
  • 反応時間: ~32 hours
  • 実験の流れ:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (参考用のみ)
動物試験:

[8]

+ 展開
  • 動物モデル: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~10 ng
  • 投与方法: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 466.53
化学式

C28H26N4O3

CAS No. 62996-74-1
保管
in solvent
別名 CGP 41251

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

PKC信号経路図

相関PKC製品

Tags: Staurosporineを買う | Staurosporine ic50 | Staurosporine供給者 | Staurosporineを購入する | Staurosporine費用 | Staurosporine生産者 | オーダーStaurosporine | Staurosporine化学構造 | Staurosporine分子量 | Staurosporine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID